Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mergæxli - Æxlishemjandi lyf - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - risperidonum inn - mixtúra, lausn - 1 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - risperidonum inn - filmuhúðuð tafla - 1 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfs-/innrennslisstofn, lausn - 2 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ceftazidimum inn - stungulyfsstofn, lausn - 1 g

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - risperidonum inn - filmuhúðuð tafla - 2 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - risperidonum inn - filmuhúðuð tafla - 1 mg